PLX Financial Facts
COST OF REVENUES: -4.25MRESEARCH AND DEVELOPMENT EXPENSES, NET: -5.06M
See Full Income Statement
Total liabilities net of capital deficiency: 70.47M
COMMITMENTS: 0
See Full Balance Sheet
Protalix Biotherapeutics, Inc. (PLX) Earnings
|
Expand Research on PLX
| Next EPS Date | N/A | EPS Growth Rate | N/A |
|---|---|---|---|
| Average EPS % Beat Rate | -115.0% | Revenue Growth Rate | N/A |
| Average % Move 1-Wk after EPS | -17.7% | Normal Earnings Time | Before Open |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
3/12/26  |
Q425 | N/A | $0.04 | N/A | N/A | $18.35M | N/A | N/A | N/A | ||
| 11/13/25 | Q325 | $0.03 | $0.07 | -$0.04 | $17.67M | $17.79M | N/A |  | | Details | |
| 8/14/25 | Q225 | -$0.04 | $0.11 | -$0.15 | $25.77M | $23.1M | N/A | | | Details | |
| 5/9/25 | Q125 | -$0.05 | $0.03 | -$0.08 | $10.11M | $21.6M | N/A | | | Details | |
| 8/14/24 | Q224 | -$0.03 | $0.00 | -$0.03 | $13.47M | N/A | N/A | | | Details | |
| 5/8/24 | Q124 | N/A | -$0.02 | N/A | N/A | $9.2M | N/A | N/A | N/A | ||
| 3/27/24 | Q423 | N/A | -$0.03 | N/A | N/A | $8.15M | N/A | N/A | N/A | ||
| 11/6/23 | Q323 | -$0.04 | -$0.04 | $0.00 | $10.34M | $10M | N/A | | | Details |
